Compare Stocks: LSTA, XBIT, BOLD, and ALPS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.40	$0.41	$0.23 ▼ $15.00	$66.56M	-0.1	77,149 shs	108,784 shs
BOLD Boundless Bio	$2.81 -1.1%	$2.71	$0.96 ▼ $3.16	$64.60M	-0.03	90,979 shs	23,226 shs
LSTA Lisata Therapeutics	$1.54 -1.3%	$1.82	$0.99 ▼ $5.07	$14.06M	0.94	554,390 shs	157,863 shs
XBIT XBiotech	$2.19 +0.9%	$2.27	$2.09 ▼ $3.44	$66.16M	0.85	50,034 shs	18,229 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	+3.90%	+25.00%	-42.69%	+39,999,900.00%
BOLD Boundless Bio	-1.06%	-1.75%	-0.71%	+100.71%	+146.49%
LSTA Lisata Therapeutics	-1.28%	-17.20%	+41.28%	-56.25%	-27.36%
XBIT XBiotech	+0.92%	+0.46%	-4.78%	-7.59%	-19.49%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.40	$0.41	$0.23 ▼ $15.00	$66.56M	-0.1	77,149 shs	108,784 shs
BOLD Boundless Bio	$2.81 -1.1%	$2.71	$0.96 ▼ $3.16	$64.60M	-0.03	90,979 shs	23,226 shs
LSTA Lisata Therapeutics	$1.54 -1.3%	$1.82	$0.99 ▼ $5.07	$14.06M	0.94	554,390 shs	157,863 shs
XBIT XBiotech	$2.19 +0.9%	$2.27	$2.09 ▼ $3.44	$66.16M	0.85	50,034 shs	18,229 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	+3.90%	+25.00%	-42.69%	+39,999,900.00%
BOLD Boundless Bio	-1.06%	-1.75%	-0.71%	+100.71%	+146.49%
LSTA Lisata Therapeutics	-1.28%	-17.20%	+41.28%	-56.25%	-27.36%
XBIT XBiotech	+0.92%	+0.46%	-4.78%	-7.59%	-19.49%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPS ALPS Group Inc Ordinary Share	1.00	Sell	N/A	N/A
BOLD Boundless Bio	1.00	Sell	N/A	N/A
LSTA Lisata Therapeutics	1.67	Reduce	N/A	N/A
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LSTA, XBIT, BOLD, and ALPS Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/1/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	BOLD Boundless Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	LSTA Lisata Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/6/2026	ALPS ALPS Group Inc Ordinary Share	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/30/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/23/2026	BOLD Boundless Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Reduce

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPS ALPS Group Inc Ordinary Share	$4.86M	13.70	N/A	N/A	($3.10) per share	-0.13
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$4.41 per share	N/A
LSTA Lisata Therapeutics	$170K	81.62	N/A	N/A	$1.66 per share	0.93
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPS ALPS Group Inc Ordinary Share	-$2.01M	$0.33	1.21	N/A	N/A	N/A	N/A	N/A	N/A
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
LSTA Lisata Therapeutics	-$16.59M	-$1.64	N/A	N/A	N/A	N/A	-116.08%	-90.55%	11/5/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest LSTA, XBIT, BOLD, and ALPS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPS ALPS Group Inc Ordinary Share	$0.37	92.50%	N/A	112.12%	N/A
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPS ALPS Group Inc Ordinary Share	N/A	0.36	0.27
BOLD Boundless Bio	N/A	9.48	9.48
LSTA Lisata Therapeutics	N/A	3.69	3.69
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPS ALPS Group Inc Ordinary Share	27.90%
BOLD Boundless Bio	N/A
LSTA Lisata Therapeutics	8.94%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ALPS ALPS Group Inc Ordinary Share	0.81%
BOLD Boundless Bio	23.10%
LSTA Lisata Therapeutics	9.10%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPS ALPS Group Inc Ordinary Share	N/A	166.40 million	165.05 million	N/A
BOLD Boundless Bio	64	22.75 million	17.49 million	No Data
LSTA Lisata Therapeutics	30	9.01 million	8.19 million	Not Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

LSTA, XBIT, BOLD, and ALPS Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - What's Next?

September 15 at 3:21 AM | americanbankingnews.com

XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving Average - Time to Sell?

September 3, 2026 | marketbeat.com

XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened

August 26, 2026 | marketbeat.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LSTA, XBIT, BOLD, and ALPS Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.40 0.00 (0.00%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$0.40 0.00 (0.00%)

As of 09/15/2026 05:44 PM Eastern

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Boundless Bio NASDAQ:BOLD

$2.81 -0.03 (-1.06%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$2.80 0.00 (-0.18%)

As of 09/15/2026 06:36 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Lisata Therapeutics NASDAQ:LSTA

$1.54 -0.02 (-1.28%)

Closing price 09/15/2026 04:00 PM Eastern

Extended Trading

$1.52 -0.02 (-1.49%)

As of 09/15/2026 07:02 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

XBiotech NASDAQ:XBIT

$2.19 +0.02 (+0.92%)

Closing price 09/15/2026 03:59 PM Eastern

Extended Trading

$2.18 0.00 (-0.23%)

As of 09/15/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, XBIT, BOLD, and ALPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, XBIT, BOLD, and ALPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, XBIT, BOLD, and ALPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, XBIT, BOLD, and ALPS Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Boundless Bio NASDAQ:BOLD

Lisata Therapeutics NASDAQ:LSTA

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LSTA, XBIT, BOLD, and ALPS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LSTA, XBIT, BOLD, and ALPS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LSTA, XBIT, BOLD, and ALPS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LSTA, XBIT, BOLD, and ALPS Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Boundless Bio NASDAQ:BOLD

Lisata Therapeutics NASDAQ:LSTA

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools